Which has better earnings & valuation, AVBP or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is AVBP or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Oruka Therapeutics N/A -21.65% -20.88%

Does the media prefer AVBP or ORKA?

In the previous week, ArriVent BioPharma had 34 more articles in the media than Oruka Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat ArriVent BioPharma's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 8 Negative mention(s) 4 Very Negative mention(s) Neutral Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or AVBP?

In the previous week, ArriVent BioPharma had 22 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 17 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.32 beat ArriVent BioPharma's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 8 Negative mention(s) 4 Very Negative mention(s) Neutral

Does the media refer more to TVTX or AVBP?

In the previous week, ArriVent BioPharma had 33 more articles in the media than Travere Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.19 beat ArriVent BioPharma's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 8 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, COGT or AVBP?

Cogent Biosciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A

Is COGT or AVBP more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% ArriVent BioPharma N/A -50.26% -46.66%

Does the media favor AVBP or PTCT?

In the previous week, ArriVent BioPharma had 23 more articles in the media than PTC Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.43 beat ArriVent BioPharma's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 8 Negative mention(s) 4 Very Negative mention(s) Neutral PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

ArriVent BioPharma (AVBP) Competitors

$16.09 -0.37 (-2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$16.50 +0.41 (+2.57%)

As of 07:40 PM Eastern

Compare

AVBP vs. ORKA, CRSP, TVTX, COGT, and PTCT

Should you buy ArriVent BioPharma stock or one of its competitors? ArriVent BioPharma's main competitors and comparable companies include Oruka Therapeutics (ORKA), CRISPR Therapeutics (CRSP), Travere Therapeutics (TVTX), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ArriVent BioPharma compare to Oruka Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

ArriVent BioPharma has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Oruka Therapeutics' return on equity of -21.65% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Oruka Therapeutics	N/A	-21.65%	-20.88%

ArriVent BioPharma presently has a consensus price target of $27.44, suggesting a potential upside of 66.73%. Oruka Therapeutics has a consensus price target of $128.91, suggesting a potential upside of 60.43%. Given ArriVent BioPharma's higher possible upside, equities research analysts plainly believe ArriVent BioPharma is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, ArriVent BioPharma had 34 more articles in the media than Oruka Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat ArriVent BioPharma's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Oruka Therapeutics beats ArriVent BioPharma on 9 of the 13 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

ArriVent BioPharma has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,420.05	-$581.60M	-$4.76	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
ArriVent BioPharma	N/A	-50.26%	-46.66%

In the previous week, ArriVent BioPharma had 22 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 17 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.32 beat ArriVent BioPharma's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

CRISPR Therapeutics currently has a consensus target price of $67.94, indicating a potential upside of 31.80%. ArriVent BioPharma has a consensus target price of $27.44, indicating a potential upside of 66.73%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.68
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Summary

CRISPR Therapeutics and ArriVent BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Travere Therapeutics has higher revenue and earnings than ArriVent BioPharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.99	-$25.55M	-$0.46	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

ArriVent BioPharma has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. ArriVent BioPharma's return on equity of -50.26% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
ArriVent BioPharma	N/A	-50.26%	-46.66%

In the previous week, ArriVent BioPharma had 33 more articles in the media than Travere Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.19 beat ArriVent BioPharma's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

Travere Therapeutics currently has a consensus price target of $69.50, suggesting a potential upside of 33.60%. ArriVent BioPharma has a consensus price target of $27.44, suggesting a potential upside of 66.73%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

9.5% of ArriVent BioPharma shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

ArriVent BioPharma beats Travere Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

9.5% of ArriVent BioPharma shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cogent Biosciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

ArriVent BioPharma's return on equity of -50.26% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
ArriVent BioPharma	N/A	-50.26%	-46.66%

In the previous week, ArriVent BioPharma had 38 more articles in the media than Cogent Biosciences. MarketBeat recorded 39 mentions for ArriVent BioPharma and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat ArriVent BioPharma's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
ArriVent BioPharma	Neutral

Cogent Biosciences presently has a consensus price target of $51.56, indicating a potential upside of 73.12%. ArriVent BioPharma has a consensus price target of $27.44, indicating a potential upside of 66.73%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cogent Biosciences is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Cogent Biosciences has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

ArriVent BioPharma beats Cogent Biosciences on 9 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to PTC Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

PTC Therapeutics has higher revenue and earnings than ArriVent BioPharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
PTC Therapeutics	$1.73B	3.03	$682.64M	-$0.58	N/A

ArriVent BioPharma has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. PTC Therapeutics' return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
PTC Therapeutics	-3.80%	N/A	-1.32%

In the previous week, ArriVent BioPharma had 23 more articles in the media than PTC Therapeutics. MarketBeat recorded 39 mentions for ArriVent BioPharma and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.43 beat ArriVent BioPharma's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

ArriVent BioPharma presently has a consensus target price of $27.44, suggesting a potential upside of 66.73%. PTC Therapeutics has a consensus target price of $98.25, suggesting a potential upside of 56.15%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe ArriVent BioPharma is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

9.5% of ArriVent BioPharma shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ArriVent BioPharma and PTC Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$811.60M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-4.44	9.71	193.11	18.97
Price / Sales	N/A	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	2.16	16.95	10.71	6.03
Net Income	-$166.31M	-$22.69M	$3.50B	$380.34M
7 Day Performance	6.63%	-4.83%	-3.18%	-3.04%
1 Month Performance	-44.52%	-12.20%	-6.61%	-5.16%
1 Year Performance	-23.01%	8.87%	3.69%	-2.48%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.7053 of 5 stars	$16.09 -2.2%	$27.44 +70.6%	-21.1%	$811.60M	N/A	N/A	77	News Coverage Analyst Downgrade Analyst Revision
ORKA Oruka Therapeutics	2.8695 of 5 stars	$80.18 -5.0%	$128.91 +60.8%	+228.1%	$5.59B	N/A	N/A	68	Insider Trade
CRSP CRISPR Therapeutics	3.4331 of 5 stars	$54.00 -5.8%	$67.94 +25.8%	-29.5%	$5.54B	$3.51M	N/A	393
TVTX Travere Therapeutics	3.1859 of 5 stars	$55.98 -2.9%	$69.50 +24.2%	+106.8%	$5.44B	$490.73M	N/A	497
COGT Cogent Biosciences	2.8363 of 5 stars	$30.38 -1.6%	$51.56 +69.7%	+83.0%	$5.36B	N/A	N/A	258	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. ORKA, CRSP, TVTX, COGT, and PTCT

How does ArriVent BioPharma compare to Oruka Therapeutics?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to Travere Therapeutics?

Summary

How does ArriVent BioPharma compare to Cogent Biosciences?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. ORKA, CRSP, TVTX, COGT, and PTCT

How does ArriVent BioPharma compare to Oruka Therapeutics?

Which has more risk & volatility, AVBP or ORKA?

Which has better earnings & valuation, AVBP or ORKA?

Is AVBP or ORKA more profitable?

Do analysts recommend AVBP or ORKA?

Does the media prefer AVBP or ORKA?

Do insiders and institutionals hold more shares of AVBP or ORKA?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Which has higher earnings & valuation, CRSP or AVBP?

Is CRSP or AVBP more profitable?

Does the media refer more to CRSP or AVBP?

Do analysts prefer CRSP or AVBP?

Do insiders and institutionals believe in CRSP or AVBP?

Which has more volatility and risk, CRSP or AVBP?

Summary

How does ArriVent BioPharma compare to Travere Therapeutics?

Which has higher valuation and earnings, TVTX or AVBP?

Is TVTX or AVBP more profitable?

Does the media refer more to TVTX or AVBP?

Do analysts recommend TVTX or AVBP?

Do insiders & institutionals hold more shares of TVTX or AVBP?

Which has more volatility and risk, TVTX or AVBP?

Summary

How does ArriVent BioPharma compare to Cogent Biosciences?

Do insiders and institutionals have more ownership in COGT or AVBP?

Which has stronger valuation and earnings, COGT or AVBP?

Is COGT or AVBP more profitable?

Does the media refer more to COGT or AVBP?

Do analysts recommend COGT or AVBP?

Which has more volatility & risk, COGT or AVBP?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Which has preferable earnings & valuation, AVBP or PTCT?

Is AVBP or PTCT more profitable?

Does the media favor AVBP or PTCT?

Which has more risk and volatility, AVBP or PTCT?

Do analysts recommend AVBP or PTCT?

Do institutionals & insiders hold more shares of AVBP or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools